Home/ Stocks/ CRBU

Caribou Biosciences, Inc. Common Stock

CRBU XNAS

$1.65 +0.02 (+1.20%) ▲ 15-min delayed

Open

$1.65

High

$1.67

Low

$1.63

Volume

806.0K

Market Cap

$162.66M

About Caribou Biosciences, Inc. Common Stock

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 97 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$2.40M	$-25,085,000	$-0.26
FY 2025	$11.16M	$-148,125,000	$-1.59
Q3 2025	$2.20M	$-27,548,000	$-0.30
Q2 2025	$2.67M	$-54,098,000	$-0.58

Related Market News

No specific coverage for CRBU yet. Check out our latest market news or earnings calendar.

Get CRBU Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Caribou Biosciences, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.